Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?

Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?
November 24, 2020

In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products, including:

  • The rebranding of generics to original brand reference products
  • The impact of the falsified medicines framework on parallel trade
  • Further points of attention when verifying in light of the BMS conditions

Contact

  • Philippe de Jong

    Partner

  • Kirian Claeyé

    Counsel

Recommended articles

February 09, 2023

New Mdeon rules applicable as from 1 January 2023

Mdeon, the legally recognised Belgian ethical platform for healthcare professionals and the pharmaceutical industry, announced several new ethics rules applying from 1 January 2023.

Read on
January 30, 2023

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines

The Belgian Competition Authority fines Novartis for abuse of collective dominance regarding eye disease medicines On 23 January 2018, the European Court of Justice (“ECJ”) handed down its judgment (C-179/16) in relation to Novartis’ Lucentis® and Roche’s Avastin® eye disease medicines, and ruled that disseminating misleading information on the off-label use of a medicine could constitute a restriction of competition ‘by object’. Exactly 5 years later, on 23 January 2023, the Belgian Competition Authority (“BCA”) imposed a fine on Novartis Pharma SA and Novartis AG (together “Novartis”) for abuse of collective dominance resulting from disseminating misleading information regarding risks in relation to the off label use of Roche’s Avastin®.

Read on
January 16, 2023

When are IP holders liable for enforcing a later invalidated IP right?

At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.

Read on